

RARE HETEROZYGOUS VARIANTS IN GENES OF THE LEPTIN-MELANOCORTIN SATIETY PATHWAY CONTRIBUTE TO CHILDHOOD OBESITY

G. Á. Martos-Moreno^{1,2,3}, R. García-Rastrilla¹, Á. Martín-Rivada¹, L.A. Pérez-Jurado^{4,5,6}, J. Argente^{1,2,3,7}.

1. Department of Pediatric Endocrinology. Hospital Infantil Universitario Niño Jesús. Instituto de Investigación La Princesa Madrid, Spain.
2. Department of Pediatrics. Universidad Autónoma de Madrid. Madrid, Spain.
3. Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III. Madrid, Spain.
4. Genetics Unit, Universitat Pompeu Fabra, Barcelona, Spain.
5. Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
6. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.
7. IMDEA Institute. Madrid, Spain.

The authors have nothing to disclose

INTRODUCTION

- The central melanocortin signaling pathway is highly involved in the control of energy homeostasis and metabolism, receiving and integrating numerous peripheral metabolic signals, such as leptin or insulin.
- Biallelic mutations in several genes of the leptin-melanocortin pathway have been reported in severe obesity. However, whether and how **heterozygous rare sequence variants (hetRSVs)** in genes of this satiety pathway contribute to the development of obesity is poorly explored.

AIM

- Our aim was to investigate whether **hetRSVs** in 13 genes involved in the leptin-melanocortin pathway contribute to childhood obesity by comparing their prevalence in 1066 children and adolescents with obesity and a country-matched control population.

PATIENTS AND METHODS

- A transversal study of 1066 children and adolescents (below age 18 years) with obesity (BMI Z-score > 2, **OB**) was carried-out with next generation sequencing (NGS) analysis of *ADCY3*, *CPE*, *LEP*, *LEPR*, *MC3R*, *MC4R*, *MRAP2*, *NCOA1*, *PCSK1*, *POMC*, *SH2B1*, *SIM1* and *TBX3* performed.
- The population was made up of 48.6% females / 51.4% males of whom 54.4% were prepubertal children / 45.6% adolescents and 71.7% Caucasians. Mean population age and BMI Z-score were 10.37 ± 3.44 years and +4.38 ± 1.77, respectively.
- Rare (population frequency <0.01) heterozygous variants with a Combined Annotation Dependent Depletion (CADD) score of “deleteriousness” >20 and >25 in each gene were considered and their relative frequency compared with that in a country matched control population (**C**, n=1012).

RESULTS

- A total of 199 patients of the OB group (18.8%) and 81 controls (8.0%) carried heterozygous RSVs with **CADD > 20** in the 13 selected genes (**OR=2.64**, 95% CI = 2.00-3.47, **p<0.0001**).
- Out of them, 101 patients vs. 45 controls harboured **hetRSVs** with **CADD > 25** (9.47% vs. 4.44%, **OR = 2.25**, 95% CI = 1.56-3.23, **p<0.0001**).
- No significant differences** in the prevalence of hetRSVs between groups were observed in:
 - **ADCY3** (MIM* 600291. ADENYLATE CYCLASE 3)
 - **LEP** (MIM* 164160. LEPTIN) - **LEPR** (MIM* 601007. LEPTIN RECEPTOR)
 - **TBX3** (MIM* 601621. T-BOX TRANSCRIPTION FACTOR 3)
- In contrast, **OB** showed a significantly **higher prevalence of hetRSVs with CADD > 20** in:
 - **CPE** (MIM* 114855. CARBOXYPEPTIDASE E).
 - **MRAP2** (MIM* 615410. MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN 2).
 - **MC3R** (MIM* 155540. MELANOCORTIN 3 RECEPTOR).
 - **MC4R** (MIM* 155541. MELANOCORTIN 4 RECEPTOR).
 - **NCOA1** (MIM* 602691. NUCLEAR RECEPTOR COACTIVATOR 1) (*Alternative nomenclature: SRC1*).
 - **PCSK1** (MIM* 162150. PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 1).
 - **POMC** (MIM* 176830. PROOPIOMELANOCORTIN).
 - **SH2B1** (MIM* 608937. SH2B ADAPTOR PROTEIN 1).
 - **SIM1** (MIM* 603128. SIM bHLH TRANSCRIPTION FACTOR 1).
- These intergroup differences were particularly relevant for **POMC**, **PCSK1**, **MC4R** and **NCOA1** (Table).

CONCLUSIONS

- The prevalence of heterozygous variants in leptin-melanocortin pathway genes, particularly in POMC, PCSK1, MC4R and NCOA1, in childhood obesity is higher than in general population, so they likely contribute to the early development of obesity in these patients.**

CADD	Variants (n): OB			Variants (n): C			Intergroup comparison
	> 25	20-25	Total >20	>25	20-25	Total >20	
ADCY3	9	7	16	5	5	10	N.S.
CPE	4	8	12	2	2	4	p < 0.05
LEP	0	0	0	1	0	1	N.S.
LEPR	9	4	13	8	5	13	N.S.
MC3R	6	6	12	5	0	5	p < 0.05
MC4R	13	10	23	2	1	3	p < 0.01
MRAP2	6	2	8	2	0	2	p < 0.05
NCOA1	14	24	38	6	6	12	p < 0.01
PCSK1	5	6	11	0	4	4	p < 0.01
POMC	21	8	29	1	5	6	p < 0.01
SH2B1	5	6	11	4	1	5	p < 0.05
SIM1	7	8	15	3	4	7	p < 0.05
TBX3	2	9	11	6	3	9	N.S.
13 genes	101	98	199	45	36	81	p < 0.0001

Table legend: Abbreviations: **C:** Control group; **CADD:** Combined Annotation Dependent Depletion score; **N.S.:** Non significant, **OB:** Obesity group.

ACKNOWLEDGEMENTS

This work was supported by CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and the Instituto de Salud Carlos III, FIS (FIS grant numbers PI09/91060; FIS 10/00747; FIS 13/01295; and FIS 16/00485).

CONTACT INFORMATION

G. Á. Martos-Moreno: gabrielangelmartos@yahoo.es
J. Argente: jesus.argente@fundacionendo.org